PRESS RELEASE published on 12/16/2024 at 07:00, 1 year 8 months ago Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial Relief Therapeutics announces final readout of PKU GOLIKE clinical trial showing superior metabolic control during prolonged fasting in PKU patients. Results aim to promote awareness and adoption of PKU GOLIKE Clinical Trial Relief Therapeutics PKU GOLIKE Phenylketonuria Metabolic Control
BRIEF published on 12/13/2024 at 23:05, 1 year 8 months ago Relief Therapeutics to End SEC Reporting Obligations with Form 15F Filing OTCQB SIX Swiss Exchange Relief Therapeutics SEC Reporting Form 15F
BRIEF published on 12/13/2024 at 23:05, 1 year 8 months ago Relief Therapeutics va mettre fin à ses obligations de déclaration auprès de la SEC avec le dépôt du formulaire 15F OTCQB Bourse Suisse SIX THÉRAPEUTIQUE DE SECOURS Formulaire 15F Rapports De La SEC
PRESS RELEASE published on 12/13/2024 at 23:00, 1 year 8 months ago Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations Relief Therapeutics announces filing of Form 15F to terminate SEC reporting obligations, maintaining listing on SIX Swiss Exchange and U.S. over-the-counter market SIX Swiss Exchange Relief Therapeutics SEC Reporting Form 15F U.S. OTCQB
BRIEF published on 11/11/2024 at 07:05, 1 year 10 months ago Relief Therapeutics Reports Positive Outcomes in RLF-TD011 Trial for Epidermolysis Bullosa Relief Therapeutics RLF-TD011 Clinical Trial Results Epidermolysis Bullosa Microbiome Diversity
BRIEF published on 11/11/2024 at 07:05, 1 year 10 months ago Relief Therapeutics rapporte des résultats positifs dans l'essai RLF-TD011 pour l'épidermolyse bulleuse THÉRAPEUTIQUE DE SECOURS RLF-TD011 Résultats Des Essais Cliniques Epidermolyse Bulleuse Diversité Du Microbiome
PRESS RELEASE published on 11/11/2024 at 07:00, 1 year 10 months ago Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa Relief Therapeutics reports positive final results from RLF-TD011 clinical trial for Epidermolysis Bullosa, showing effective wound healing and microbiome diversity improvements Clinical Trial Relief Therapeutics RLF-TD011 Epidermolysis Bullosa Microbiome Diversity
BRIEF published on 11/04/2024 at 07:05, 1 year 10 months ago Relief Therapeutics and Renexxion Consider Reverse Merger Biotechnology Shareholder Value Healthcare Reverse Merger Gastrointestinal Disorders
BRIEF published on 11/04/2024 at 07:05, 1 year 10 months ago Relief Therapeutics et Renexxion envisagent une fusion inversée Biotechnologie Valeur Actionnariale Soins De Santé Fusion Inversée Troubles Gastro-intestinaux
PRESS RELEASE published on 11/04/2024 at 07:00, 1 year 10 months ago Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger Relief Therapeutics signs non-binding letter of intent with Renexxion for reverse merger, aiming to create a combined entity with an expanded therapeutic pipeline Biopharmaceutical Relief Therapeutics Therapeutic Pipeline Reverse Merger Renexxion
Published on 09/11/2026 at 04:00, 8 hours 32 minutes ago Torq Announces Debt Settlement and Corporate Update
Published on 09/10/2026 at 22:25, 14 hours 7 minutes ago Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 15:20, 21 hours 12 minutes ago MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 21 hours 32 minutes ago All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Published on 09/11/2026 at 11:43, 49 minutes ago Skyborn reaches Financial Close on the Gennaker offshore wind farm project
Published on 09/11/2026 at 11:35, 57 minutes ago EQS-Adhoc: Correction of a release from 10/09/2026, 19:35 CET/CEST - United Internet AG: Group subsidiaries 1&1 AG and IONOS Group SE launch transformation programs
Published on 09/11/2026 at 11:30, 1 hour 2 minutes ago Galimedix Therapeutics to present functional feasibility data from Phase 2 eDREAM study in geographic atrophy at 26th EURETINA Congress
Published on 09/11/2026 at 10:15, 2 hours 17 minutes ago TCMA Receives Two National Awards, Highlighting Thailand’s Cement Industry Progress Towards Net Zero 2050
Published on 09/11/2026 at 07:00, 5 hours 32 minutes ago Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 5 hours 32 minutes ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 5 hours 32 minutes ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 17 hours 2 minutes ago Availability of the 2026 Interim Financial Report
